# Proof-of-concept Study to Evaluate the Safety and Immunomodulatory Effects of SCV 07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Chronic Hepatitis C Who Have Relapsed

> **NCT00968357** · PHASE2 · COMPLETED · sponsor: **SciClone Pharmaceuticals** · enrollment: 40 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** SCV-07

## Key facts

- **NCT ID:** NCT00968357
- **Lead sponsor:** SciClone Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2012-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00968357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00968357, "Proof-of-concept Study to Evaluate the Safety and Immunomodulatory Effects of SCV 07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Chronic Hepatitis C Who Have Relapsed". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00968357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*